|
WO2017182427A1
|
|
Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
|
|
WO2017134140A1
|
|
Bispecific t cell engaging antibody constructs
|
|
TW201728339A
|
|
Pharmaceutical composition comprising bispecific antibody constructs
|
|
TW201708261A
|
|
Antibody constructs for DLL3 and CD3
|
|
TW201708256A
|
|
Antibody constructs for MSLN and CD3
|
|
TW201708257A
|
|
Antibody constructs for FLT3 and CD3
|
|
TW201706307A
|
|
Antibody constructs for CD70 and CD3
|
|
TW201716441A
|
|
Antibody constructs for EGFRVIII and CD3
|
|
WO2016184931A1
|
|
B-cell depletion as a diagnostic marker
|
|
MX2017001402A
|
|
Antibody constructs for cdh19 and cd3.
|
|
AR095374A1
|
|
UNION MOLECULES FOR BCMA AND CD3
|
|
US2014228316A1
|
|
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
|
SI2352763T1
|
|
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
